FDA To Review AstraZeneca Diabetes Drug For Heart Risks

Law360, New York (February 11, 2014, 7:54 PM EST) -- The U.S. Food and Drug Administration launched an investigation Tuesday into the safety of an AstraZeneca PLC diabetes drug after a recent study found that users of the medication were more likely to suffer heart failure than a control group.

The agency asked AstraZeneca to supply it with clinical trial data in order to examine a possible link between the drugmaker's saxagliptin and heart failure. Saxagliptin is marketed as Onglyza and Kombiglyze XR.

The request stems from a study that appeared in the New England Journal...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.